These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25896423)

  • 1. Effect of L-theanine on glutamatergic function in patients with schizophrenia.
    Ota M; Wakabayashi C; Sato N; Hori H; Hattori K; Teraishi T; Ozawa H; Okubo T; Kunugi H
    Acta Neuropsychiatr; 2015 Oct; 27(5):291-6. PubMed ID: 25896423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation.
    Ota M; Ishikawa M; Sato N; Hori H; Sasayama D; Hattori K; Teraishi T; Nakata Y; Kunugi H
    Acta Psychiatr Scand; 2012 Jul; 126(1):72-8. PubMed ID: 22432602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.
    Merritt K; McGuire PK; Egerton A; ; Aleman A; Block W; Bloemen OJN; Borgan F; Bustillo JR; Capizzano AA; Coughlin JM; De la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galinska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes OD; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan M; Kim SY; Kunugi H; Lauriello J; Liemburg EJ; Mcilwain ME; Modinos G; Mouchlianitis ED; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone JM; Szulc A; Taylor R; Thakkar K; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H
    JAMA Psychiatry; 2021 Jun; 78(6):667-681. PubMed ID: 33881460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A
    Ćurčić-Blake B; Bais L; Sibeijn-Kuiper A; Pijnenborg HM; Knegtering H; Liemburg E; Aleman A
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():132-139. PubMed ID: 28546056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
    Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
    JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
    Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
    JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.
    Tarumi R; Tsugawa S; Noda Y; Plitman E; Honda S; Matsushita K; Chavez S; Sawada K; Wada M; Matsui M; Fujii S; Miyazaki T; Chakravarty MM; Uchida H; Remington G; Graff-Guerrero A; Mimura M; Nakajima S
    Neuropsychopharmacology; 2020 Mar; 45(4):632-640. PubMed ID: 31842203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Nutrients; 2015 Oct; 7(10):8767-82. PubMed ID: 26506383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis.
    Merritt K; McCutcheon RA; Aleman A; Ashley S; Beck K; Block W; Bloemen OJN; Borgan F; Boules C; Bustillo JR; Capizzano AA; Coughlin JM; David A; de la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galińska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes O; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan MS; Kim SY; King B; Kunugi H; Lauriello J; León-Ortiz P; Liemburg E; Mcilwain ME; Modinos G; Mouchlianitis E; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Patel T; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Reyes-Madrigal F; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone J; Szulc A; Taylor R; Thakkar KN; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H; McGuire P; Egerton A;
    Mol Psychiatry; 2023 May; 28(5):2039-2048. PubMed ID: 36806762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.
    Jelen LA; King S; Horne CM; Lythgoe DJ; Young AH; Stone JM
    Eur Neuropsychopharmacol; 2019 Dec; 29(2):222-234. PubMed ID: 30558824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Spitzberg K; Kersting A; Arolt V; Heindel W; Pfleiderer B
    Schizophr Res; 2005 Mar; 73(2-3):153-7. PubMed ID: 15653258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.
    Iwata Y; Nakajima S; Plitman E; Caravaggio F; Kim J; Shah P; Mar W; Chavez S; De Luca V; Mimura M; Remington G; Gerretsen P; Graff-Guerrero A
    Biol Psychiatry; 2019 Apr; 85(7):596-605. PubMed ID: 30389132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications.
    Pillinger T; Rogdaki M; McCutcheon RA; Hathway P; Egerton A; Howes OD
    Psychopharmacology (Berl); 2019 Jul; 236(7):1985-1997. PubMed ID: 30820633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
    Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
    Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
    Théberge J; Al-Semaan Y; Williamson PC; Menon RS; Neufeld RW; Rajakumar N; Schaefer B; Densmore M; Drost DJ
    Am J Psychiatry; 2003 Dec; 160(12):2231-3. PubMed ID: 14638596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression - an MR spectroscopy study.
    Murck H; Schubert MI; Schmid D; Schüssler P; Steiger A; Auer DP
    J Psychiatr Res; 2009 Jan; 43(3):175-80. PubMed ID: 18533184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study.
    Hidese S; Ota M; Wakabayashi C; Noda T; Ozawa H; Okubo T; Kunugi H
    Acta Neuropsychiatr; 2017 Apr; 29(2):72-79. PubMed ID: 27396868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.
    Duarte JMN; Xin L
    Neurochem Res; 2019 Jan; 44(1):102-116. PubMed ID: 29616444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.